{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T14:52:23Z","timestamp":1790779943705,"version":"4.1.0"},"reference-count":315,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology &amp; Therapeutics"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.pharmthera.2021.107937","type":"journal-article","created":{"date-parts":[[2021,6,24]],"date-time":"2021-06-24T07:08:52Z","timestamp":1624518532000},"page":"107937","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":83,"special_numbering":"C","title":["Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders"],"prefix":"10.1016","volume":"229","author":[{"given":"Adrian","family":"Newman-Tancredi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ronan Y.","family":"Depoort\u00e8re","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark S.","family":"Kleven","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Ko\u0142aczkowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luc","family":"Zimmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2021.107937_bb0005","doi-asserted-by":"crossref","first-page":"18208","DOI":"10.1073\/pnas.1012104107","article-title":"Correction of respiratory disorders in a mouse model of Rett syndrome","volume":"107","author":"Abdala","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0010","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1165\/rcmb.2013-0372OC","article-title":"Effect of Sarizotan, a 5-HT1a and D2-like receptor agonist, on respiration in three mouse models of Rett syndrome","volume":"50","author":"Abdala","year":"2014","journal-title":"American Journal of Respiratory Cell and Molecular Biology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0015","series-title":"Pharmacology 2017 London, UK","article-title":"Pre-clinical study of NLX-101 for the treatment of apnoeas in two mouse models of Rett syndrome","author":"Abdala Sheikh","year":"2016"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0020","series-title":"Pharmacology 2017","first-page":"PB082","article-title":"NLX-101 ameliorates ventilatory responses to hypercapnia in a mouse model of Rett syndrome","author":"Abdala Sheikh","year":"2017"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0025","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1016\/S0022-3565(25)20679-6","article-title":"Novel benzodioxan derivative, 5-[3-[((2S)-1,4-benzodioxan-2-ylmethyl) amino]propoxy]-1,3-benzodioxole HCl (MKC-242), with anxiolytic-like and antidepressant-like effects in animal models","volume":"278","author":"Abe","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0030","doi-asserted-by":"crossref","first-page":"110210","DOI":"10.1016\/j.pnpbp.2020.110210","article-title":"The 5-HT1A receptor as a serotonergic target for neuroprotection in cerebral ischemia","volume":"109","author":"Aguiar","year":"2020","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0035","doi-asserted-by":"crossref","first-page":"109832","DOI":"10.1016\/j.pnpbp.2019.109832","article-title":"Activation of 5-HT1A postsynaptic receptors by NLX-101 results in functional recovery and an increase in neuroplasticity in mice with brain ischemia","volume":"99","author":"Aguiar","year":"2019","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0040","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1503\/jpn.180209","article-title":"Genetic, epigenetic and posttranscriptional mechanisms for treatment of major depression: The 5-HT1A receptor gene as a paradigm","volume":"44","author":"Albert","year":"2019","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0045","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.biochi.2018.10.015","article-title":"The 5-HT1A receptor: Signaling to behavior","volume":"161","author":"Albert","year":"2019","journal-title":"Biochimie"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0050","doi-asserted-by":"crossref","first-page":"199","DOI":"10.3389\/fnbeh.2014.00199","article-title":"Serotonin-prefrontal cortical circuitry in anxiety and depression phenotypes: Pivotal role of pre- and post-synaptic 5-HT1A receptor expression","volume":"8","author":"Albert","year":"2014","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0055","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.neuropharm.2008.06.029","article-title":"Assessing human 5-HT function in vivo with pharmacoMRI","volume":"55","author":"Anderson","year":"2008","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0060","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.neubiorev.2018.12.002","article-title":"Chronic unpredictable mild stress for modeling depression in rodents:Meta-analysis of model reliability","volume":"99","author":"Antoniuk","year":"2018","journal-title":"Neuroscience and Biobehavioral Reviews"},{"issue":"Suppl. 1","key":"10.1016\/j.pharmthera.2021.107937_bb0065","doi-asserted-by":"crossref","first-page":"S8","DOI":"10.1097\/00005344-198300051-00002","article-title":"Intrinsic activity: Partial agonists and partial antagonists","volume":"5","author":"Ariens","year":"1983","journal-title":"Journal of Cardiovascular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0070","doi-asserted-by":"crossref","first-page":"139","DOI":"10.2174\/138945006775515446","article-title":"Pindolol augmentation of antidepressant response","volume":"7","author":"Artigas","year":"2006","journal-title":"Current Drug Targets"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0075","doi-asserted-by":"crossref","first-page":"1285","DOI":"10.1017\/S1461145709991222","article-title":"F15599, a highly selective post-synaptic 5-HT1A receptor agonist: In-vivo profile in behavioural models of antidepressant and serotonergic activity","volume":"13","author":"Assie","year":"2010","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0080","series-title":"Society for neuroscience - 36th annual meeting","article-title":"Pharmacological profile of F15599, a highly selective serotonin 5-HT1A receptor agonist","author":"Assi\u00e9","year":"2006"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0085","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1111\/j.1476-5381.1996.tb15749.x","article-title":"Possible in vivo 5-HT reuptake blocking properties of 8-OH-DPAT assessed by measuring hippocampal extracellular 5-HT using microdialysis in rats","volume":"119","author":"Assie","year":"1996","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0090","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1038\/sj.bjp.0706859","article-title":"Rapid desensitization of somatodendritic 5-HT1A receptors by chronic administration of the high-efficacy 5-HT1A agonist, F13714: A microdialysis study in the rat","volume":"149","author":"Assie","year":"2006","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0095","series-title":"British association for psychopharmacology summer meeting","article-title":"Differential effects of 5-HT1A receptor agonists on extracellular levels of 5-HT in hippocampus and of dopamine in frontal cortex of freely moving rats","author":"Assi\u00e9","year":"2008"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0100","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1007\/s00213-007-0762-7","article-title":"Putative antipsychotics with pronounced agonism at serotonin 5-HT1A and partial agonist activity at dopamine D2 receptors disrupt basal PPI of the startle reflex in rats","volume":"193","author":"Auclair","year":"2007","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0105","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1038\/sj.npp.1301015","article-title":"Actions of novel antipsychotic agents on apomorphine-induced PPI disruption: Influence of combined serotonin 5-HT1A receptor activation and dopamine D2 receptor blockade","volume":"31","author":"Auclair","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0110","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1016\/j.jchemneu.2006.01.006","article-title":"A comparison of in vivo and in vitro neuroimaging of 5-HT 1A receptor binding sites in the cat brain","volume":"31","author":"Aznavour","year":"2006","journal-title":"Journal of Chemical Neuroanatomy"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0115","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1016\/j.neuropharm.2006.09.023","article-title":"[18F]MPPF as a tool for the in vivo imaging of 5-HT1A receptors in animal and human brain","volume":"52","author":"Aznavour","year":"2007","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0120","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0045072","article-title":"Impaired chemosensitivity of mouse dorsal raphe serotonergic neurons overexpressing serotonin 1A (Htr1a) receptors","volume":"7","author":"Baccini","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0125","first-page":"399","article-title":"Studies on the sites and mechanisms of 5-HT1A receptor-mediated in vivo actions","volume":"84","author":"Bagdy","year":"1996","journal-title":"Acta Physiologica Hungarica"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0130","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/S0014-2999(97)00021-6","article-title":"Comparison of relative potencies of i.v. and i.c.v. administered 8-OH-DPAT gives evidence of different sites of action for hypothermia, lower lip retraction and tail flicks","volume":"323","author":"Bagdy","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0135","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.ejpain.2003.09.002","article-title":"Role of spinal 5-HT(1A) receptors in morphine analgesia and tolerance in rats","volume":"8","author":"Bardin","year":"2004","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0140","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1159\/000068404","article-title":"Profound, non-opioid analgesia produced by the high-efficacy 5-HT1A agonist F 13640 in the formalin model of tonic nociceptive pain","volume":"67","author":"Bardin","year":"2003","journal-title":"Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0145","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1124\/pr.118.015552","article-title":"International union of basic and clinical pharmacology. CX. Classification of receptors for 5-hydroxytryptamine; pharmacology and function","volume":"73","author":"Barnes","year":"2021","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0150","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0149-7634(94)90038-8","article-title":"Anxiolytic and antidepressant mechanisms of 5-HT1A drugs in the pigeon: Contributions from behavioral studies","volume":"18","author":"Barrett","year":"1994","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0155","doi-asserted-by":"crossref","first-page":"26633","DOI":"10.1038\/srep26633","article-title":"Selective serotonin 5-HT1A receptor biased agonists elicitdistinct brain activation patterns: A pharmacoMRI study","volume":"6","author":"Becker","year":"2016","journal-title":"Scientific Reports"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0160","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1111\/cns.12306","article-title":"A postmortem study to compare agonist and antagonist 5-HT1A receptor-binding sites in Alzheimer\u2019s disease","volume":"20","author":"Becker","year":"2014","journal-title":"CNS Neuroscience & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0165","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1016\/0014-2999(94)90728-5","article-title":"Role of dorsal and median raphe nuclei in lower lip retraction in rats","volume":"263","author":"Berendsen","year":"1994","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0170","first-page":"421","article-title":"Development of functionally selective agonists as novel therapeutic agents","volume":"3","author":"Berg","year":"2006","journal-title":"Drug Discovery Today: Therapeutic Strategies"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0175","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.2967\/jnumed.116.188037","article-title":"The use of microdosing in the development of small organic and protein therapeutics","volume":"58","author":"Bergstrom","year":"2017","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0180","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s00228-003-0643-x","article-title":"Positron emission tomography microdosing: A new concept with application in tracer and early clinical drug development","volume":"59","author":"Bergstrom","year":"2003","journal-title":"European Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0185","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1111\/j.1476-5381.1991.tb12342.x","article-title":"Direct evidence for an important species difference in the mechanism of 8-OH-DPAT-induced hypothermia","volume":"103","author":"Bill","year":"1991","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0190","doi-asserted-by":"crossref","first-page":"70","DOI":"10.2174\/09298673113209990215","article-title":"PET radiotracers for molecular imaging of serotonin 5-HT1A receptors","volume":"21","author":"Billard","year":"2014","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0195","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/S0924-977X(02)00173-6","article-title":"The pharmacology of putative early-onset antidepressant strategies","volume":"13","author":"Blier","year":"2003","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0200","doi-asserted-by":"crossref","first-page":"1125","DOI":"10.1016\/S0022-3565(24)38065-6","article-title":"Selective antiaggressive effects of alnespirone in resident-intruder test are mediated via 5-hydroxytryptamine1A receptors: A comparative pharmacological study with 8-hydroxy-2-dipropylaminotetralin, ipsapirone, buspirone, eltoprazine, and WAY-100635","volume":"288","author":"de Boer","year":"1999","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0205","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/S0893-133X(00)00092-0","article-title":"Somatodendritic 5-HT(1A) autoreceptors mediate the anti-aggressive actions of 5-HT(1A) receptor agonists in rats: An ethopharmacological study with S-15535, alnespirone, and WAY-100635","volume":"23","author":"de Boer","year":"2000","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0210","doi-asserted-by":"crossref","first-page":"937","DOI":"10.1007\/s00213-015-4173-x","article-title":"Anti-aggressive effects of the selective high-efficacy \u201cbiased\u201d 5-HT(1)A receptor agonists F15599 and F13714 in male WTG rats","volume":"233","author":"de Boer","year":"2016","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0215","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.2174\/156802606778522186","article-title":"Pharmacophore models for metabotropic 5-HT receptor ligands","volume":"6","author":"Bojarski","year":"2006","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0220","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1016\/j.bmc.2005.09.060","article-title":"Structure-intrinsic activity relationship studies in the group of 1-imido\/amido substituted 4-(4-arylpiperazin-1-yl)cyclohexane derivatives; new, potent 5-HT1A receptor agents with anxiolytic- like activity","volume":"14","author":"Bojarski","year":"2006","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0225","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1016\/j.bmc.2004.12.041","article-title":"1-Aryl-4-(4-succinimidobutyl)piperazines and their conformationally constrained analogues: Synthesis, binding to serotonin (5-HT1A, 5-HT2A, 5-HT7), alpha1-adrenergic, and dopaminergic D2 receptors, and in vivo 5-HT1A functional characteristics","volume":"13","author":"Bojarski","year":"2005","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0230","doi-asserted-by":"crossref","first-page":"7167","DOI":"10.1021\/jm100835q","article-title":"Novel pyridylmethylamines as highly selective 5-HT(1A) superagonists","volume":"53","author":"Bollinger","year":"2010","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22041927","article-title":"The role of central serotonin neurons and 5-HT heteroreceptor complexes in the pathophysiology of depression: A historical perspective and future prospects","volume":"22","author":"Borroto-Escuela","year":"2021","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0240","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fncel.2017.00037","article-title":"Understanding the role of GPCR heteroreceptor complexes in modulating the brain networks in health and disease","volume":"11","author":"Borroto-Escuela","year":"2017","journal-title":"Frontiers in Cellular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0245","doi-asserted-by":"crossref","DOI":"10.3390\/molecules23061341","article-title":"Receptor(\u2212)receptor interactions in multiple 5-HT1A heteroreceptor complexes in raphe-hippocampal 5-HT transmission and their relevance for depression and its treatment","volume":"23","author":"Borroto-Escuela","year":"2018","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0250","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1007\/BF00308809","article-title":"Neuropathological stageing of Alzheimer-related changes","volume":"82","author":"Braak","year":"1991","journal-title":"Acta Neuropathologica"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0255","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.pain.2008.11.009","article-title":"5-HT7 receptor activation inhibits mechanical hypersensitivity secondary to capsaicin sensitization in mice","volume":"141","author":"Brenchat","year":"2009","journal-title":"Pain"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0260","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1111\/j.1365-2125.2003.02046.x","article-title":"Recent advances in drug action and therapeutics: Relevance of novel concepts in G-protein-coupled receptor and signal transduction pharmacology","volume":"57","author":"Brink","year":"2004","journal-title":"British Journal of Clinical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0265","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1097\/FBP.0b013e3282f62cb2","article-title":"Effects of antipsychotics and reference monoaminergic ligands on marble burying behavior in mice","volume":"19","author":"Bruins Slot","year":"2008","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0270","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/S0014-2999(03)01566-8","article-title":"Tolerance and inverse tolerance to the hyperalgesic and analgesic actions, respectively, of the novel analgesic, F 13640","volume":"466","author":"Bruins Slot","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0275","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.expneurol.2018.01.010","article-title":"Neurophysiological effects in cortico-basal ganglia-thalamic circuits of antidyskinetic treatment with 5-HT1A receptor biased agonists","volume":"302","author":"Brys","year":"2018","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0280","doi-asserted-by":"crossref","first-page":"350","DOI":"10.1016\/j.neuropharm.2008.09.004","article-title":"Region-specific changes in 5-HT1A agonist-induced extracellular signal-regulated kinases 1\/2 phosphorylation in rat brain: A quantitative ELISA study","volume":"56","author":"Buritova","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0285","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2005.03.016","article-title":"Effects of the high-efficacy 5-HT1A receptor agonist, F 13640 in the formalin pain model: A c-Fos study","volume":"514","author":"Buritova","year":"2005","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0290","series-title":"Society for neuroscience - 37th annual meeting","article-title":"F15599, a 5-HT1A agonist that preferentially targets post-synaptic receptors: I activity on ERK1\/2 phosphorylation and c-fos induction","author":"Buritova","year":"2007"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0295","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/S0006-8993(03)02582-4","article-title":"The novel analgesic and high-efficacy 5-HT1A receptor agonist, F 13640 induces c-Fos protein expression in spinal cord dorsal horn neurons","volume":"974","author":"Buritova","year":"2003","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0300","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.2174\/0929867054367220","article-title":"Derivatives as 5HT1A receptor ligands--past and present","volume":"12","author":"Caliendo","year":"2005","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0305","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1016\/S0028-3908(97)00094-4","article-title":"Comparative behavioural profiles of buspirone and its metabolite 1-(2-pyrimidinyl)-piperazine (1-PP) in the murine elevated plus-maze","volume":"36","author":"Cao","year":"1997","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0310","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0315","first-page":"8.10A.1","article-title":"Rodent models of depression: Forced swim and tail suspension behavioral despair tests in rats and mice","author":"Castagne","year":"2011","journal-title":"Current Protocols in Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0320","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1007\/s40263-013-0071-0","article-title":"Serotonin 5-HT1A receptors as targets for agents to treat psychiatric disorders: Rationale and current status of research","volume":"27","author":"Celada","year":"2013","journal-title":"CNS Drugs"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0325","doi-asserted-by":"crossref","first-page":"25","DOI":"10.3389\/fnint.2013.00025","article-title":"Serotonin modulation of cortical neurons and networks","volume":"7","author":"Celada","year":"2013","journal-title":"Frontiers in Integrative Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0330","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1111\/j.1743-6109.2010.01961.x","article-title":"The serotonin transporter plays an important role in male sexual behavior: A study in serotonin transporter knockout rats","volume":"8","author":"Chan","year":"2011","journal-title":"The Journal of Sexual Medicine"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107937_bb0335","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.therap.2020.12.006","article-title":"Innovative approaches in CNS drug discovery","volume":"76","author":"Charveriat","year":"2020","journal-title":"Therapie"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0340","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.brainres.2015.11.026","article-title":"5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma","volume":"1640","author":"Cheng","year":"2016","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0345","doi-asserted-by":"crossref","first-page":"18474","DOI":"10.3390\/ijms160818474","article-title":"Functional selectivity and antidepressant activity of serotonin 1A receptor ligands","volume":"16","author":"Chilmonczyk","year":"2015","journal-title":"International Journal of Molecular Sciences"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0350","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1126\/science.1094987","article-title":"Cognitive inflexibility after prefrontal serotonin depletion","volume":"304","author":"Clarke","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0355","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/S0022-3565(25)13071-1","article-title":"Lack of 5-hydroxytryptamine1A-mediated inhibition of adenylyl cyclase in dorsal raphe of male and female rats","volume":"277","author":"Clarke","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107937_bb0360","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/s00259-019-04473-7","article-title":"(18)F-F13640 PET imaging of functional receptors in humans","volume":"47","author":"Colom","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0365","doi-asserted-by":"crossref","first-page":"622423","DOI":"10.3389\/fnins.2021.622423","article-title":"[(18)F]F13640, a 5-HT1A receptor radiopharmaceutical sensitive to brain serotonin fluctuations","volume":"15","author":"Colom","year":"2021","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0370","doi-asserted-by":"crossref","DOI":"10.3389\/fnmol.2019.00255","article-title":"Is there a role for GPCR agonist radiotracers in PET neuroimaging?","volume":"12","author":"Colom","year":"2019","journal-title":"Frontiers in Molecular Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0375","first-page":"40","article-title":"5-HT(1A) receptor activation: New molecular and neuroadaptive mechanisms of pain relief","volume":"7","author":"Colpaert","year":"2006","journal-title":"Current Opinion in Investigational Drugs"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0380","doi-asserted-by":"crossref","first-page":"945","DOI":"10.1016\/S0028-3908(02)00119-3","article-title":"Large-amplitude 5-HT1A receptor activation: A new mechanism of profound, central analgesia","volume":"43","author":"Colpaert","year":"2002","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0385","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.resp.2013.02.015","article-title":"Serotonergic mechanisms are necessary for central respiratory chemoresponsiveness in situ","volume":"186","author":"Corcoran","year":"2013","journal-title":"Respiratory Physiology & Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0390","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1016\/bs.pbr.2021.01.032","article-title":"Serotonin\/dopamine interaction in the induction and maintenance of L-DOPA-induced dyskinesia: An update","volume":"261","author":"Corsi","year":"2021","journal-title":"Progress in Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0395","first-page":"1980","article-title":"A 18F-MPPF PET normative database of 5-HT1A receptor binding in men and women over aging","volume":"46","author":"Costes","year":"2005","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0400","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1177\/026988119901300310","article-title":"Comparative effects of serotonergic agonists with varying efficacy at the 5-HT(1A) receptor on core body temperature: Modification by the selective 5-HT(1A) receptor antagonist WAY 100635","volume":"13","author":"Cryan","year":"1999","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0405","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.ejphar.2008.07.040","article-title":"Agonist-directed trafficking of signalling at serotonin 5-HT2A, 5-HT2B and 5-HT2C-VSV receptors mediated Gq\/11 activation and calcium mobilisation in CHO cells","volume":"594","author":"Cussac","year":"2008","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0410","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1016\/j.cellsig.2012.04.010","article-title":"Mu-opioid and 5-HT1A receptors heterodimerize and show signalling crosstalk via G protein and MAP-kinase pathways","volume":"24","author":"Cussac","year":"2012","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0415","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1016\/j.pharmthera.2008.10.004","article-title":"Unfaithful neurotransmitter transporters: Focus on serotonin uptake and implications for antidepressant efficacy","volume":"121","author":"Daws","year":"2009","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0420","doi-asserted-by":"crossref","first-page":"7108","DOI":"10.1016\/S0021-9258(20)79672-9","article-title":"A ternary complex model explains the agonist-specific binding properties of the adenylate cyclase-coupled beta-adrenergic receptor","volume":"255","author":"De Lean","year":"1980","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0425","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.euroneuro.2010.04.005","article-title":"F15599, a preferential post-synaptic 5-HT1A receptor agonist: Activity in models of cognition in comparison with reference 5-HT1A receptor agonists","volume":"20","author":"Depoortere","year":"2010","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0430","doi-asserted-by":"crossref","first-page":"113082","DOI":"10.1016\/j.bbr.2020.113082","article-title":"NLX-101, a highly selective 5-HT1A receptor biased agonist, mediates antidepressant-like activity in rats via prefrontal cortex 5-HT1A receptors","volume":"401","author":"Depoortere","year":"2021","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0435","first-page":"1","article-title":"Marble burying in NMRI male mice is preferentially sensitive to pre- versus postsynaptic 5-HT1A receptor biased agonists","author":"Depoortere","year":"2020","journal-title":"Pharmacology"},{"issue":"7","key":"10.1016\/j.pharmthera.2021.107937_bb0440","doi-asserted-by":"crossref","first-page":"3101","DOI":"10.1021\/acschemneuro.8b00661","article-title":"Serotonin 5-HT1A receptor biased agonists display differential anxiolytic activity in a rat social interaction model","volume":"10","author":"Depoortere","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0445","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.parkreldis.2020.08.009","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic effects in MPTP-treated macaques","volume":"78","author":"Depoortere","year":"2020","journal-title":"Parkinsonism & Related Disorders"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0450","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1177\/0269881119860666","article-title":"Cortical 5-hydroxytryptamine 1A receptor biased agonist, NLX-101, displays rapid-acting antidepressant-like properties in the rat chronic mild stress model","volume":"33","author":"Depoortere","year":"2019","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0455","doi-asserted-by":"crossref","first-page":"147493","DOI":"10.1016\/j.brainres.2021.147493","article-title":"NLX-101, a cortical 5-HT1A receptor biased agonist, reverses scopolamine-induced deficit in the delayed non-matching to position model of cognition","volume":"1765","author":"Depoortere","year":"2021","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0460","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S0014-2999(02)02640-7","article-title":"The 5-HT(1A) receptor agonist F 13640 attenuates mechanical allodynia in a rat model of trigeminal neuropathic pain","volume":"456","author":"Deseure","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0465","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1016\/j.ejpain.2004.01.002","article-title":"Effects of the combined continuous administration of morphine and the high-efficacy 5-HT1A agonist, F 13640 in a rat model of trigeminal neuropathic pain","volume":"8","author":"Deseure","year":"2004","journal-title":"European Journal of Pain"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0470","doi-asserted-by":"crossref","first-page":"10831","DOI":"10.1523\/JNEUROSCI.2999-05.2005","article-title":"Involvement of 5-HT1A receptors in prefrontal cortex in the modulation of dopaminergic activity: Role in atypical antipsychotic action","volume":"25","author":"Diaz-Mataix","year":"2005","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0475","article-title":"Functional approaches to the study of G-protein-coupled receptors in postmortem brain tissue: [(35)S]GTPgammaS binding assays combined with immunoprecipitation","author":"Diez-Alarcia","year":"2021","journal-title":"Pharmacological Reports"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0480","doi-asserted-by":"crossref","DOI":"10.1523\/ENEURO.0065-19.2019","article-title":"New insights from 22-kHz ultrasonic vocalizations to characterize fear responses: Relationship with respiration and brain oscillatory dynamics","volume":"6","author":"Dupin","year":"2019","journal-title":"eNeuro"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0485","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1046\/j.1471-4159.2001.00300.x","article-title":"Reduced activation and expression of ERK1\/2 MAP kinase in the post-mortem brain of depressed suicide subjects","volume":"77","author":"Dwivedi","year":"2001","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0490","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1017\/S1461145709990575","article-title":"Aberrant extracellular signal-regulated kinase (ERK)1\/2 signalling in suicide brain: Role of ERK kinase 1 (MEK1)","volume":"12","author":"Dwivedi","year":"2009","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0495","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1002\/(SICI)1098-2396(200002)35:2<144::AID-SYN7>3.0.CO;2-K","article-title":"Agonist high and low affinity state ratios predict drug intrinsic activity and a revised ternary complex mechanism at serotonin 5-HT(2A) and 5-HT(2C) receptors","volume":"35","author":"Egan","year":"2000","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0500","doi-asserted-by":"crossref","first-page":"7070","DOI":"10.1073\/pnas.94.13.7070","article-title":"Activation of heteromeric G protein-gated inward rectifier K+ channels overexpressed by adenovirus gene transfer inhibits the excitability of hippocampal neurons","volume":"94","author":"Ehrengruber","year":"1997","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0505","doi-asserted-by":"crossref","first-page":"109862","DOI":"10.1016\/j.cellsig.2020.109862","article-title":"Biased agonism at chemokine receptors","volume":"78","author":"Eiger","year":"2021","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0510","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/0006-2952(90)90642-X","article-title":"Physical evidence of the coupling of solubilized 5-HT1A binding sites with G regulatory proteins","volume":"39","author":"Emerit","year":"1990","journal-title":"Biochemical Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0515","doi-asserted-by":"crossref","first-page":"40","DOI":"10.3389\/fnbeh.2020.00040","article-title":"Pharmacological studies on the role of 5-HT1 A receptors in male sexual behavior of wildtype and serotonin transporter knockout rats","volume":"14","author":"Esquivel-Franco","year":"2020","journal-title":"Frontiers in Behavioral Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0520","first-page":"25","article-title":"Biased opioid ligands","author":"Faouzi","year":"2020","journal-title":"Molecules"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0525","doi-asserted-by":"crossref","first-page":"14848","DOI":"10.1016\/S0021-9258(18)63778-0","article-title":"Effector coupling mechanisms of the cloned 5-HT1A receptor","volume":"264","author":"Fargin","year":"1989","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0530","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1111\/j.1476-5381.1978.tb07001.x","article-title":"Can social interaction be used to measure anxiety?","volume":"62","author":"File","year":"1978","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0535","doi-asserted-by":"crossref","first-page":"107997","DOI":"10.1016\/j.neuropharm.2020.107997","article-title":"The selective 5-HT1A receptor agonist, NLX-112, exerts anti-dyskinetic and anti-parkinsonian-like effects in MPTP-treated marmosets","volume":"167","author":"Fisher","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0540","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/S0022-3565(25)20660-7","article-title":"WAY-100635, a potent and selective 5-hydroxytryptamine1A antagonist, increases serotonergic neuronal activity in behaving cats: Comparison with (S)-WAY-100135","volume":"278","author":"Fornal","year":"1996","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0545","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1515\/bmc-2018-0013","article-title":"Biased receptor functionality versus biased agonism in G-protein-coupled receptors","volume":"9","author":"Franco","year":"2018","journal-title":"Biomolecular Concepts"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0550","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1016\/j.neuropharm.2018.05.001","article-title":"5-HT1A receptor stimulation in the medial prefrontal cortex mediates the antidepressant effects of mGlu2\/3 receptor antagonist in mice","volume":"137","author":"Fukumoto","year":"2018","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0555","doi-asserted-by":"crossref","first-page":"371","DOI":"10.1093\/ijnp\/pyx116","article-title":"Role of 5-HT1A receptor stimulation in the medial prefrontal cortex in the sustained antidepressant effects of ketamine","volume":"21","author":"Fukumoto","year":"2018","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0560","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/0002-9343(86)90331-1","article-title":"Metabolism and disposition of buspirone","volume":"80","author":"Gammans","year":"1986","journal-title":"The American Journal of Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0565","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.drudis.2016.01.016","article-title":"Emerging treatment mechanisms for depression: Focus on glutamate and synaptic plasticity","volume":"21","author":"Gerhard","year":"2016","journal-title":"Drug Discovery Today"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0570","doi-asserted-by":"crossref","first-page":"4283","DOI":"10.1021\/bi00180a024","article-title":"Selective activation of inhibitory G-protein alpha-subunits by partial agonists of the human 5-HT1A receptor","volume":"33","author":"Gettys","year":"1994","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0575","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1124\/mol.119.119214","article-title":"Intrinsic efficacy of opioid ligands and its importance for apparent bias, operational analysis, and therapeutic window","volume":"98","author":"Gillis","year":"2020","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0580","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1111\/j.1526-4610.2009.01575.x","article-title":"Triptans, serotonin agonists, and serotonin syndrome (serotonin toxicity): A review","volume":"50","author":"Gillman","year":"2010","journal-title":"Headache"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0585","doi-asserted-by":"crossref","DOI":"10.1007\/s00213-021-05849-0","article-title":"The selective 5-HT1A receptor biased agonists, F15599 and F13714, show antidepressant-like properties after a single administration in the mouse model of unpredictable chronic mild stress","author":"G\u0142uch-Lutwin","year":"2021","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0595","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1002\/mds.21226","article-title":"Sarizotan as a treatment for dyskinesias in Parkinson\u2019s disease: A double-blind placebo-controlled trial","volume":"22","author":"Goetz","year":"2007","journal-title":"Movement Disorders"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0600","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1038\/85899","article-title":"A mouse Mecp2-null mutation causes neurological symptoms that mimic Rett syndrome","volume":"27","author":"Guy","year":"2001","journal-title":"Nature Genetics"},{"issue":"10","key":"10.1016\/j.pharmthera.2021.107937_bb0590","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1111\/bph.13071","article-title":"Divergent effects of the \u201cbiased\u201d, 5-HT1A receptor agonists F15599 and F13714 in a novel object pattern separation task","volume":"172","author":"van Goethem","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0605","series-title":"Improving pattern separation and cognition: Effects of pharmacological interventions on rodent behavior and neuroplasticity","author":"van Hagen","year":"2020"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0610","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/0014-2999(89)90251-3","article-title":"8-OH-DPAT increases corticosterone but not other 5-HT1A receptor-dependent responses more in females","volume":"164","author":"Haleem","year":"1989","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0615","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1111\/j.1471-4159.1985.tb07155.x","article-title":"[3H]8-hydroxy-2-(di-n-propylamino)tetralin binding to pre- and postsynaptic 5-hydroxytryptamine sites in various regions of the rat brain","volume":"44","author":"Hall","year":"1985","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0620","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.ejphar.2004.01.031","article-title":"8-OH-DPAT acts on both 5-HT1A and 5-HT7 receptors to induce hypothermia in rodents","volume":"487","author":"Hedlund","year":"2004","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0625","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1007\/s00210-010-0551-4","article-title":"[3H]F13640, a novel, selective and high-efficacy serotonin 5-HT1A receptor agonist radioligand","volume":"382","author":"Heusler","year":"2010","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0630","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1016\/j.neuropharm.2005.05.001","article-title":"Differential ion current activation by human 5-HT1A receptors in Xenopus oocytes: Evidence for agonist-directed trafficking of receptor signalling","volume":"49","author":"Heusler","year":"2005","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0635","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1038\/sj.jcbfm.9600326","article-title":"Measurement of serotonin 5-HT1A receptor binding using positron emission tomography and [carbonyl-(11)C]WAY-100635-considerations on the validity of cerebellum as a reference region","volume":"27","author":"Hirvonen","year":"2007","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0640","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1016\/0024-3205(91)90216-X","article-title":"Effect of the 5-HT1A receptor agonist 8-OH-DPAT on the release of 5-HT in dorsal and median raphe-innervated rat brain regions as measured by in vivo microdialysis","volume":"48","author":"Hjorth","year":"1991","journal-title":"Life Sciences"},{"issue":"2","key":"10.1016\/j.pharmthera.2021.107937_bb0645","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00213-011-2561-4","article-title":"The role of 5-HT1A receptors in phencyclidine (PCP)-induced novel object recognition (NOR) deficit in rats","volume":"221","author":"Horiguchi","year":"2012","journal-title":"Psychopharmacology."},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107937_bb0650","doi-asserted-by":"crossref","first-page":"207","DOI":"10.2217\/nmt-2018-0017","article-title":"5-HT1A agonists and dyskinesia in Parkinson\u2019s disease: A pharmacological perspective","volume":"8","author":"Huot","year":"2018","journal-title":"Neurodegener Dis Manag"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0655","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.neuropharm.2015.05.033","article-title":"The highly-selective 5-HT agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque","volume":"97","author":"Huot","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0660","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.neulet.2005.05.056","article-title":"Defect in normal developmental increase of the brain biogenic amine concentrations in the mecp2-null mouse","volume":"386","author":"Ide","year":"2005","journal-title":"Neuroscience Letters"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0665","series-title":"Society for neuroscience","article-title":"Activity of serotonin 5-HT1A receptor biased agonists in rat models of Parkinson\u2019s disease: Potential for improved therapeutic management","volume":"vol. 63.13\/FF1","author":"Iderberg","year":"2013"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0670","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2015.01.012","article-title":"Activity of serotonin 5-HT receptor \u201cbiased agonists\u201d in rat models of Parkinson\u2019s disease and l-DOPA-induced dyskinesia","volume":"93C","author":"Iderberg","year":"2015","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0675","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.expneurol.2015.05.021","article-title":"NLX-112, a novel 5-HT1A receptor agonist for the treatment of L-DOPA-induced dyskinesia: Behavioral and neurochemical profile in rat","volume":"271","author":"Iderberg","year":"2015","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0680","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/0028-3908(88)90134-7","article-title":"8-Hydroxy-2-(di-n-propylamino) tetralin, a selective serotonin1A receptor agonist, blocks haloperidol-induced catalepsy by an action on raphe nuclei medianus and dorsalis","volume":"27","author":"Invernizzi","year":"1988","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0685","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.1124\/jpet.106.110429","article-title":"In 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine-treated primates, the selective 5-hydroxytryptamine 1a agonist (R)-(+)-8-OHDPAT inhibits levodopa-induced dyskinesia but only with increased motor disability","volume":"319","author":"Iravani","year":"2006","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0690","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/j.pbb.2004.07.015","article-title":"Effect of 5-HT1B\/D receptor agonist and antagonist administration on motor function in haloperidol and MPTP-treated common marmosets","volume":"79","author":"Jackson","year":"2004","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0695","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1007\/s00702-021-02303-5","article-title":"Serotonin-specific neurons differentiated from human iPSCs form distinct subtypes with synaptic protein assembly","volume":"128","author":"Jansch","year":"2021","journal-title":"Journal of Neural Transmission (Vienna)"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0700","doi-asserted-by":"crossref","first-page":"1040","DOI":"10.1021\/acschemneuro.7b00443","article-title":"Activity of serotonin 5-HT1A receptor biased agonists in rat: Anxiolytic and antidepressant-like properties","volume":"9","author":"Jastrzebska-Wiesek","year":"2018","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0705","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1007\/s00702-011-0703-9","article-title":"Continuous drug delivery in early- and late-stage Parkinson\u2019s disease as a strategy for avoiding dyskinesia induction and expression","volume":"118","author":"Jenner","year":"2011","journal-title":"Journal of Neural Transmission"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0710","doi-asserted-by":"crossref","first-page":"1956","DOI":"10.1111\/j.1476-5381.2011.01685.x","article-title":"Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn","volume":"165","author":"Jeong","year":"2012","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0715","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0014-2999(97)10113-3","article-title":"[3H]8-OH-DPAT labels a 5-HT site coupled to inhibition of phosphoinositide hydrolysis in the dorsal raphe","volume":"329","author":"Johnson","year":"1997","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0720","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/j.resp.2009.04.017","article-title":"Breathing disorders in Rett syndrome: Progressive neurochemical dysfunction in the respiratory network after birth","volume":"168","author":"Katz","year":"2009","journal-title":"Respiratory Physiology & Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0725","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.euroneuro.2015.12.039","article-title":"The 5-HT1A receptor in major depressive disorder","volume":"26","author":"Kaufman","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0730","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1096\/fj.00-0438rev","article-title":"Inverse, protean, and ligand-selective agonism: Matters of receptor conformation","volume":"15","author":"Kenakin","year":"2001","journal-title":"FASEB Journal"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0735","doi-asserted-by":"crossref","first-page":"1393","DOI":"10.1124\/mol.107.040352","article-title":"Functional selectivity through protean and biased agonism: Who steers the ship?","volume":"72","author":"Kenakin","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0740","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/S0022-3565(25)33349-5","article-title":"Theoretical and practical problems with the assessment of intrinsic efficacy of agonists: Efficacy of reputed beta-1 selective adrenoceptor agonists for beta-2 adrenoceptors","volume":"223","author":"Kenakin","year":"1982","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0745","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1038\/nrd2838","article-title":"Cellular assays as portals to seven-transmembrane receptor-based drug discovery","volume":"8","author":"Kenakin","year":"2009","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0750","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/S0026-895X(25)14062-5","article-title":"A quantitative analysis of beta-adrenergic receptor interactions: Resolution of high and low affinity states of the receptor by computer modeling of ligand binding data","volume":"17","author":"Kent","year":"1980","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0755","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/j.ejphar.2005.09.003","article-title":"The novel analgesic, F 13640, produces intra- and postoperative analgesia in a rat model of surgical pain","volume":"523","author":"Kiss","year":"2005","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0760","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/0014-2999(95)00324-E","article-title":"Modification of behavioral effects of 8-hydroxy-2-(di-n-propylamino)tetralin following chronic ethanol consumption in the rat: Evidence for the involvement of 5-HT1A receptors in ethanol dependence","volume":"281","author":"Kleven","year":"1995","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0765","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S0022-3565(24)36843-0","article-title":"Pharmacological characterization of in vivo properties of putative mixed 5-HT1A agonist\/5-HT(2A\/2C) antagonist anxiolytics. II. Drug discrimination and behavioral observation studies in rats","volume":"282","author":"Kleven","year":"1997","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0770","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/B978-0-7020-5307-8.00007-7","article-title":"Clinical relevance of animal models of schizophrenia","volume":"62","author":"Koch","year":"2013","journal-title":"Supplements to Clinical Neurophysiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0775","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/S0014-2999(01)01011-1","article-title":"5-HT1A receptor activation and antidepressant-like effects: F 13714 has high efficacy and marked antidepressant potential","volume":"420","author":"Koek","year":"2001","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0780","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1097\/00004850-199409000-00007","article-title":"Eltoprazine in aggressive mentally handicapped patients: A double-blind, placebo- and baseline-controlled multi-centre study. The eltoprazine aggression research group","volume":"9","author":"de Koning","year":"1994","journal-title":"International Clinical Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0785","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1007\/s00221-013-3498-0","article-title":"Towards metabolically stable 5-HT7 receptor ligands: A study on 1-arylpiperazine derivatives and related isosters","volume":"230","author":"Lacivita","year":"2013","journal-title":"Experimental Brain Research"},{"issue":"8","key":"10.1016\/j.pharmthera.2021.107937_bb0790","doi-asserted-by":"crossref","first-page":"1203","DOI":"10.1007\/s00702-017-1837-1","article-title":"Serotonergic targets for the treatment of L-DOPA-induced dyskinesia","volume":"125","author":"Lanza","year":"2018","journal-title":"Journal of Neural Transmission (Vienna)"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0795","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1097\/00004647-200003000-00001","article-title":"Imaging synaptic neurotransmission with in vivo binding competition techniques: A critical review","volume":"20","author":"Laruelle","year":"2000","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0800","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2007.08.039","article-title":"Ube3a mRNA and protein expression are not decreased in Mecp2R168X mutant mice","volume":"1180","author":"Lawson-Yuen","year":"2007","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0805","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.pnpbp.2019.03.015","article-title":"Ketamine ameliorates severe traumatic event-induced antidepressant-resistant depression in a rat model through ERK activation","volume":"93","author":"Lee","year":"2019","journal-title":"Progress in Neuro-Psychopharmacology & Biological Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0810","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1016\/S0022-3565(24)36532-2","article-title":"Interactions of (+)- and (\u2212)-8- and 7-hydroxy-2-(di-n-propylamino)tetralin at human (h)D3, hD2 and h serotonin1A receptors and their modulation of the activity of serotoninergic and dopaminergic neurones in rats","volume":"280","author":"Lejeune","year":"1997","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0815","doi-asserted-by":"crossref","first-page":"969","DOI":"10.2967\/jnumed.111.101212","article-title":"Radiosynthesis and preclinical evaluation of 18F-F13714 as a fluorinated 5-HT1A receptor agonist radioligand for PET neuroimaging","volume":"53","author":"Lemoine","year":"2012","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0820","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1007\/s00259-009-1274-y","article-title":"[18F]F15599, a novel 5-HT1A receptor agonist, as a radioligand for PET neuroimaging","volume":"37","author":"Lemoine","year":"2010","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0825","series-title":"Society of nuclear medicine","article-title":"Radiosynthesis and radiopharmacological evaluation of [18F]F13714, a novel 5-HT1A receptor agonist","author":"Lemoine","year":"2011"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0830","doi-asserted-by":"crossref","first-page":"3108","DOI":"10.1021\/acschemneuro.8b00584","article-title":"Serotonin 5-HT1A receptor biased agonists induce different cerebral metabolic responses: A [18F]FDG PET study in conscious and anesthetized rats","volume":"10","author":"Levigoureux","year":"2019","journal-title":"ACS Chemical Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0835","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1152\/japplphysiol.00889.2013","article-title":"A selective 5-HT1A receptor agonist improves respiration in a mouse model of Rett syndrome","volume":"115","author":"Levitt","year":"2013","journal-title":"Journal of Applied Physiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0840","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1016\/j.ejphar.2009.04.027","article-title":"Food restriction and streptozotocin differentially modify sensitivity to the hypothermic effects of direct- and indirect-acting serotonin receptor agonists in rats","volume":"613","author":"Li","year":"2009","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0845","doi-asserted-by":"crossref","first-page":"113395","DOI":"10.1016\/j.expneurol.2020.113395","article-title":"Improvement of lower urinary tract function by a selective serotonin 5-HT1A receptor agonist, NLX-112, after chronic spinal cord injury","volume":"332","author":"Lin","year":"2020","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0850","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1111\/bph.12894","article-title":"Side effect profile of 5-HT treatments for Parkinson\u2019s disease and L-DOPA-induced dyskinesia in rats","volume":"172","author":"Lindenbach","year":"2015","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0855","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1111\/j.1476-5381.2010.00738.x","article-title":"Preferential in vivo action of F15599, a novel 5-HT1A receptor agonist, at postsynaptic 5-HT1A receptors","volume":"160","author":"Llado-Pelfort","year":"2010","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0860","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s00213-011-2569-9","article-title":"In vivo electrophysiological and neurochemical effects of the selective 5-HT1A receptor agonist, F13640, at pre- and postsynaptic 5-HT1A receptors in the rat","volume":"221","author":"Llado-Pelfort","year":"2012","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0865","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1093\/cercor\/bhr220","article-title":"5-HT1A receptor agonists enhance pyramidal cell firing in prefrontal cortex through a preferential action on GABA interneurons","volume":"22","author":"Llado-Pelfort","year":"2012","journal-title":"Cerebral Cortex"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0870","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/j.brainres.2012.04.032","article-title":"Buspirone: What is it all about?","volume":"1461","author":"Loane","year":"2012","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0875","doi-asserted-by":"crossref","first-page":"443","DOI":"10.2174\/0929867023371030","article-title":"Arylpiperazine derivatives acting at 5-HT(1A) receptors","volume":"9","author":"Lopez-Rodriguez","year":"2002","journal-title":"Current Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0880","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1016\/j.tips.2007.06.002","article-title":"GPCR functional selectivity has therapeutic impact","volume":"28","author":"Mailman","year":"2007","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0885","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.1124\/mol.106.022756","article-title":"Regional differences in the coupling of 5-hydroxytryptamine-1A receptors to G proteins in the rat brain","volume":"70","author":"Mannoury la Cour","year":"2006","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0890","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1111\/j.1471-4159.2004.02367.x","article-title":"GABA(B) receptors in 5-HT transporter- and 5-HT1A receptor-knock-out mice: Further evidence of a transduction pathway shared with 5-HT1A receptors","volume":"89","author":"Mannoury la Cour","year":"2004","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0895","doi-asserted-by":"crossref","first-page":"3753","DOI":"10.1021\/acs.jmedchem.9b00351","article-title":"Defining structure-functional selectivity relationships (SFSR) for a class of non-catechol dopamine D1 receptor agonists","volume":"62","author":"Martini","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0900","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3109\/00498259509061834","article-title":"Metabolism of [propyl-3H]-8-hydroxy-2-(N,N-di-n-propylamino)tetralin in rat","volume":"25","author":"Mason","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0905","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.3109\/00498259509061924","article-title":"Pharmacokinetics of the 5-hydroxytryptamine1A agonist 8-hydroxy-2-(N,N-di-n-propylamino)tetralin (8-OHDPAT) in the rat after intravenous and oral administration","volume":"25","author":"Mason","year":"1995","journal-title":"Xenobiotica"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0910","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1111\/jnc.12311","article-title":"Development of brainstem 5-HT1A receptor-binding sites in serotonin-deficient mice","volume":"126","author":"Massey","year":"2013","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0915","first-page":"563","article-title":"Synthesis and evaluation of 5-HT1A agonists a radioligands: Failure of G protein-coupled receptor agonists as in vivo imaging agents","volume":"40","author":"Mathis","year":"1997","journal-title":"Journal of Labelled Compounds and Radiopharmaceuticals"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0920","doi-asserted-by":"crossref","first-page":"5024","DOI":"10.1021\/jm070714l","article-title":"High-efficacy 5-HT1A agonists for antidepressant treatment: A renewed opportunity","volume":"50","author":"Maurel","year":"2007","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0925","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1007\/s00259-019-04488-0","article-title":"Advances in CNS PET: The state-of-the-art for new imaging targets for pathophysiology and drug development","volume":"47","author":"McCluskey","year":"2020","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0930","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1038\/nchembio.2527","article-title":"Structure-inspired design of beta-arrestin-biased ligands for aminergic GPCRs","volume":"14","author":"McCorvy","year":"2018","journal-title":"Nature Chemical Biology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0935","doi-asserted-by":"crossref","first-page":"3725","DOI":"10.2174\/1381612821666150605105215","article-title":"Serotonin 5-HT1A receptors and antipsychotics - an update in light of new concepts and drugs","volume":"21","author":"McCreary","year":"2015","journal-title":"Current Pharmaceutical Design"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0940","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/j.neuropharm.2016.01.013","article-title":"The novel 5-HT1A receptor agonist, NLX-112 reduces l-DOPA-induced abnormal involuntary movements in rat: A chronic administration study with microdialysis measurements","volume":"105","author":"McCreary","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0945","doi-asserted-by":"crossref","first-page":"109954","DOI":"10.1016\/j.cellsig.2021.109954","article-title":"Biased agonism at adenosine receptors","author":"McNeill","year":"2021","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0950","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.expneurol.2017.03.013","article-title":"Characterizing the differential roles of striatal 5-HT1A auto- and hetero-receptors in the reduction of l-DOPA-induced dyskinesia","volume":"292","author":"Meadows","year":"2017","journal-title":"Experimental Neurology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0955","doi-asserted-by":"crossref","first-page":"1246","DOI":"10.1016\/S0022-3565(25)24006-X","article-title":"Differential receptor reserve for 5-HT1A receptor-mediated regulation of plasma neuroendocrine hormones","volume":"271","author":"Meller","year":"1994","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0960","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/S0026-895X(25)09962-6","article-title":"Receptor reserve for 5-hydroxytryptamine1A-mediated inhibition of serotonin synthesis: Possible relationship to anxiolytic properties of 5-hydroxytryptamine1A agonists","volume":"37","author":"Meller","year":"1990","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0965","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.bbr.2008.05.016","article-title":"Does stimulation of 5-HT(1A) receptors improve cognition in schizophrenia?","volume":"195","author":"Meltzer","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0970","doi-asserted-by":"crossref","first-page":"791","DOI":"10.1124\/jpet.102.039867","article-title":"Differential actions of antiparkinson agents at multiple classes of monoaminergic receptor. I. A multivariate analysis of the binding profiles of 14 drugs at 21 native and cloned human receptor subtypes","volume":"303","author":"Millan","year":"2002","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0975","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1016\/j.tips.2008.06.007","article-title":"Signaling at G-protein-coupled serotonin receptors: Recent advances and future research directions","volume":"29","author":"Millan","year":"2008","journal-title":"Trends in Pharmacological Sciences"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0980","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1111\/j.1471-4159.1990.tb01983.x","article-title":"Induction of c-fos mRNA expression in rat striatum by neuroleptic drugs","volume":"54","author":"Miller","year":"1990","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0985","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1097\/00001756-199212000-00007","article-title":"The role of 5-HT1A and 5-HT1B receptors in spinal nociceptive transmission and in the modulation of NMDA induced behaviour","volume":"3","author":"Mjellem","year":"1992","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0990","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.pbb.2016.12.015","article-title":"Involvement of presynaptic 5-HT1A receptors in the low propensity of brexpiprazole to induce extrapyramidal side effects in rats","volume":"153","author":"Mombereau","year":"2017","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107937_bb0995","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0006-8993(92)91100-S","article-title":"Further evidence for differential affinity states of the serotonin1A receptor in rat hippocampus","volume":"590","author":"Mongeau","year":"1992","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1000","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1093\/brain\/awn235","article-title":"Combined 5-HT1A and 5-HT1B receptor agonists for the treatment of L-DOPA-induced dyskinesia","volume":"131","author":"Munoz","year":"2008","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1005","doi-asserted-by":"crossref","first-page":"26","DOI":"10.3389\/fnana.2020.00026","article-title":"Interactions between the serotonergic and other neurotransmitter systems in the Basal Ganglia: Role in Parkinson\u2019s disease and adverse effects of L-DOPA","volume":"14","author":"Munoz","year":"2020","journal-title":"Frontiers in Neuroanatomy"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1010","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3109\/10799899209074797","article-title":"Brainstem 5-hydroxytrytamine1A binding sites are not down-regulated by agonists which induce tolerance in the rat: Myoclonus and other serotonergic behaviors","volume":"12","author":"Murthy","year":"1992","journal-title":"Journal of Receptor Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1015","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1093\/bja\/88.5.679","article-title":"Antinociceptive role of 5-HT1A receptors in rat spinal cord","volume":"88","author":"Nadeson","year":"2002","journal-title":"British Journal of Anaesthesia"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1020","doi-asserted-by":"crossref","first-page":"149","DOI":"10.2217\/npy.11.12","article-title":"Biased agonism at serotonin 5-HT1A receptors: Preferential postsynaptic activity for improved therapy of CNS disorders","volume":"1","author":"Newman-Tancredi","year":"2011","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1025","series-title":"Schizophrenia research: Recent advances","first-page":"339","article-title":"Gene polymorphism at serotonin 5-HT1A receptors: Moving towards personalized medicine for psychosis and mood deficits?","author":"Newman-Tancredi","year":"2012"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1030","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.brainres.2018.03.016","article-title":"NLX-112, a highly selective 5-HT1A receptor agonist, mediates analgesia and antidepressant-like activity in rats via spinal cord and prefrontal cortex 5-HT1A receptors, respectively","volume":"1688","author":"Newman-Tancredi","year":"2018","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1035","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1124\/mol.62.3.590","article-title":"Antibody capture assay reveals bell-shaped concentration-response isotherms for h5-HT1A receptor-mediated Galphai3 activation: Conformational selection by high-efficacy agonists, and relationship to trafficking of receptor signaling","volume":"62","author":"Newman-Tancredi","year":"2002","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1040","doi-asserted-by":"crossref","first-page":"109383","DOI":"10.1016\/j.cellsig.2019.109383","article-title":"Bell-shaped agonist activation of 5-HT1A receptor-coupled Galphai3 G-proteins: Receptor density-dependent switch in receptor signaling","volume":"63","author":"Newman-Tancredi","year":"2019","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1045","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1016\/j.pbb.2017.11.002","article-title":"NLX-112, a highly selective 5-HT1A receptor agonist: Effects on body temperature and plasma corticosterone levels in rats","volume":"165","author":"Newman-Tancredi","year":"2018","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1050","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1111\/j.1476-5381.2008.00001.x","article-title":"Signal transduction and functional selectivity of F15599, a preferential post-synaptic 5-HT1A receptor agonist","volume":"156","author":"Newman-Tancredi","year":"2009","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1055","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1111\/jphp.12762","article-title":"Distinctive in vitro signal transduction profile of NLX-112, a potent and efficacious serotonin 5-HT1A receptor agonist","volume":"69","author":"Newman-Tancredi","year":"2017","journal-title":"The Journal of Pharmacy and Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1060","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1007\/s11064-018-2514-y","article-title":"Effects of the serotonin 5-HT1A receptor biased agonists, F13714 and F15599, on striatal neurotransmitter levels following L-DOPA administration in Hemi-Parkinsonian rats","volume":"43","author":"Newman-Tancredi","year":"2018","journal-title":"Neurochemical Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1065","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0006-8993(00)03020-1","article-title":"Potent serotonin (5-HT)(2A) receptor antagonists completely prevent the development of hyperthermia in an animal model of the 5-HT syndrome","volume":"890","author":"Nisijima","year":"2001","journal-title":"Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1070","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1111\/j.1476-5381.1991.tb12392.x","article-title":"Effects of 5-HT uptake inhibitors, agonists and antagonists on the burying of harmless objects by mice; a putative test for anxiolytic agents","volume":"104","author":"Njung\u2019e","year":"1991","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1075","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0091-3057(91)90590-X","article-title":"Evaluation of marble-burying behavior as a model of anxiety","volume":"38","author":"Njung\u2019e","year":"1991","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1080","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbr.2008.02.023","article-title":"The role of 5-HT1A receptors in learning and memory","volume":"195","author":"Ogren","year":"2008","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1085","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0026-895X(25)13057-5","article-title":"A molecular model for activation of a 5-hydroxytryptamine receptor","volume":"32","author":"Osman","year":"1987","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1090","first-page":"925","article-title":"The human serotonin 1A receptor expressed in neuronal cells: Toward a native environment for neuronal receptors","volume":"26","author":"Paila","year":"2006","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1095","doi-asserted-by":"crossref","first-page":"4952","DOI":"10.1021\/jm991045h","article-title":"On the bioactive conformation of NAN-190 (1) and MP3022 (2), 5-HT(1A) receptor antagonists","volume":"42","author":"Paluchowska","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb6005","article-title":"Perspectives for therapy of treatment-resistant depression.","author":"Papp","year":"2021","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1100","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1177\/0269881118791737","article-title":"Rapid antidepressant effects of deep brain stimulation of the pre-frontal cortex in an animal model of treatment-resistant depression","volume":"32","author":"Papp","year":"2018","journal-title":"Journal of Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1105","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FBP.0000000000000259","article-title":"Antidepressant, anxiolytic and procognitive effects of subacute and chronic ketamine in the chronic mild stress model of depression","volume":"28","author":"Papp","year":"2017","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1110","first-page":"1830","article-title":"In vivo delineation of 5-HT1A receptors in human brain with [18F]MPPF","volume":"41","author":"Passchier","year":"2000","journal-title":"Journal of Nuclear Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1115","doi-asserted-by":"crossref","first-page":"109865","DOI":"10.1016\/j.cellsig.2020.109865","article-title":"Biased agonism at the cannabinoid receptors - evidence from synthetic cannabinoid receptor agonists","volume":"78","author":"Patel","year":"2021","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1120","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1038\/jcbfm.2010.104","article-title":"Measuring endogenous 5-HT release by emission tomography: Promises and pitfalls","volume":"30","author":"Paterson","year":"2010","journal-title":"Journal of Cerebral Blood Flow and Metabolism"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1125","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1124\/jpet.103.055871","article-title":"Ca2+ responses in Chinese hamster ovary-K1 cells demonstrate an atypical pattern of ligand-induced 5-HT1A receptor activation","volume":"307","author":"Pauwels","year":"2003","journal-title":"The Journal of Pharmacology and Experimental Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1130","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.neuropharm.2019.05.004","article-title":"Enhanced aggressive phenotype of Tph2 knockout rats is associated with diminished 5-HT1A receptor sensitivity","volume":"153","author":"Peeters","year":"2019","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1135","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/0165-0270(85)90031-7","article-title":"Validation of open:Closed arm entries in an elevated plus-maze as a measure of anxiety in the rat","volume":"14","author":"Pellow","year":"1985","journal-title":"Journal of Neuroscience Methods"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1140","doi-asserted-by":"crossref","first-page":"105278","DOI":"10.1016\/j.nbd.2021.105278","article-title":"Identification of the 5-HT1A serotonin receptor as a novel therapeutic target in a C. elegans model of Machado-Joseph disease","volume":"152","author":"Pereira-Sousa","year":"2021","journal-title":"Neurobiology of Disease"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1145","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1124\/pr.57.2.2","article-title":"Multiple signaling states of G-protein-coupled receptors","volume":"57","author":"Perez","year":"2005","journal-title":"Pharmacological Reviews"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1150","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1021\/jm010866v","article-title":"Trans-4-[4-(Methoxyphenyl)cyclohexyl]-1-arylpiperazines: A new class of potent and selective 5-HT(1A) receptor ligands as conformationally constrained analogues of 4-[3-(5-methoxy-1,2,3,4-tetrahydronaphthalen-1-yl)propyl]-1-arylpiperazines","volume":"44","author":"Perrone","year":"2001","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1155","doi-asserted-by":"crossref","first-page":"942","DOI":"10.1021\/jm00006a013","article-title":"High affinity and selectivity on 5-HT1A receptor of 1-aryl-4-[1-tetralin alkyl]piperazines. 2","volume":"38","author":"Perrone","year":"1995","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1160","doi-asserted-by":"crossref","first-page":"109906","DOI":"10.1016\/j.cellsig.2020.109906","article-title":"Signaling diversity of mu- and delta- opioid receptor ligands: Re-evaluating the benefits of beta-arrestin\/G protein signaling bias","volume":"80","author":"Pineyro","year":"2021","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1165","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/j.neuropharm.2017.08.006","article-title":"Involvement of extracellular signal-regulated kinase (ERK) in the short and long-lasting antidepressant-like activity of NMDA receptor antagonists (zinc and Ro 25-6981) in the forced swim test in rats","volume":"125","author":"Pochwat","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1170","doi-asserted-by":"crossref","first-page":"1406","DOI":"10.1016\/j.cellsig.2010.03.019","article-title":"5-HT1A receptor-regulated signal transduction pathways in brain","volume":"22","author":"Polter","year":"2010","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1175","article-title":"The roles of serotonin in neuropsychiatric disorders","author":"Pourhamzeh","year":"2021","journal-title":"Cellular and Molecular Neurobiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1185","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0014-2999(02)02430-5","article-title":"5-HT1A receptor activation and anti-cataleptic effects: High-efficacy agonists maximally inhibit haloperidol-induced catalepsy","volume":"453","author":"Prinssen","year":"2002","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1190","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/00008877-200006000-00013","article-title":"Repeated treatment with 8-OH-DPAT induces tolerance to its ability to produce the 5-HT1A behavioural syndrome, but not to its ability to attenuate haloperidol-induced catalepsy","volume":"11","author":"Prinssen","year":"2000","journal-title":"Behavioural Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1195","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1016\/0028-3908(95)00102-C","article-title":"The effect of 5-HT1A receptor ligands in a chronic mild stress model of depression","volume":"34","author":"Przegalinski","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1200","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.3389\/fphar.2018.01146","article-title":"HBK-17, a 5-HT1A receptor ligand with anxiolytic-like activity, preferentially activates ss-Arrestin signaling","volume":"9","author":"Pytka","year":"2018","journal-title":"Frontiers in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1205","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1016\/j.bbr.2006.08.035","article-title":"The depressive-like behaviors are correlated with decreased phosphorylation of mitogen-activated protein kinases in rat brain following chronic forced swim stress","volume":"175","author":"Qi","year":"2006","journal-title":"Behavioural Brain Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1210","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1002\/syn.890180307","article-title":"5-HT1a agonist +\/\u22128-OH-DPAT modulates basal and stress-induced changes in medial prefrontal cortical dopamine","volume":"18","author":"Rasmusson","year":"1994","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1215","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00210-007-0182-6","article-title":"Differential profile of typical, atypical and third generation antipsychotics at human 5-HT7a receptors coupled to adenylyl cyclase: Detection of agonist and inverse agonist properties","volume":"376","author":"Rauly-Lestienne","year":"2007","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1220","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.cellsig.2010.08.002","article-title":"Competitive interaction of 5-HT(1A) receptors with G-protein subtypes in CHO cells demonstrated by RNA interference","volume":"23","author":"Rauly-Lestienne","year":"2011","journal-title":"Cellular Signalling"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1225","doi-asserted-by":"crossref","first-page":"21943","DOI":"10.1016\/S0021-9258(20)88276-3","article-title":"The human 5-HT1A receptor expressed in HeLa cells stimulates sodium-dependent phosphate uptake via protein kinase C","volume":"264","author":"Raymond","year":"1989","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1230","doi-asserted-by":"crossref","first-page":"1751","DOI":"10.1038\/sj.bjp.0702723","article-title":"The recombinant 5-HT1A receptor: G protein coupling and signalling pathways","volume":"127","author":"Raymond","year":"1999","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1235","doi-asserted-by":"crossref","first-page":"11064","DOI":"10.1021\/bi00092a016","article-title":"Cell-specific physical and functional coupling of human 5-HT1A receptors to inhibitory G protein alpha-subunits and lack of coupling to Gs alpha","volume":"32","author":"Raymond","year":"1993","journal-title":"Biochemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1240","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41398-020-01119-3","article-title":"Towards in vivo imaging of functionally active 5-HT1A receptors in schizophrenia: Concepts and challenges","volume":"11","author":"Razakarivony","year":"2021","journal-title":"Translational Psychiatry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1245","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1097\/ALN.0000000000000490","article-title":"5-HT1A receptor agonist Befiradol reduces fentanyl-induced respiratory depression, analgesia, and sedation in rats","volume":"122","author":"Ren","year":"2015","journal-title":"Anesthesiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1250","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.molmed.2003.10.010","article-title":"Serotonin receptors: Guardians of stable breathing","volume":"9","author":"Richter","year":"2003","journal-title":"Trends in Molecular Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1255","series-title":"Foye\u2019s principles of medicinal chemistry 8th edition","author":"Roche","year":"2019"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1260","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/sj.npp.1300062","article-title":"Modulation of serotonergic function in rat brain by VN2222, a serotonin reuptake inhibitor and 5-HT1A receptor agonist","volume":"28","author":"Romero","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1265","first-page":"572","article-title":"Trazodone is metabolized to m-chlorophenylpiperazine by CYP3A4 from human sources","volume":"26","author":"Rotzinger","year":"1998","journal-title":"Drug Metabolism and Disposition"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1270","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1097\/WNR.0000000000000781","article-title":"Response characteristics of the rat anterior cingulate cortex to ultrasonic communicative vocalizations","volume":"28","author":"Saito","year":"2017","journal-title":"Neuroreport"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1275","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.1038\/sj.bjp.0703139","article-title":"Postsynaptic 5-hydroxytryptamine(1A) receptor activation increases in vivo dopamine release in rat prefrontal cortex","volume":"129","author":"Sakaue","year":"2000","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1280","doi-asserted-by":"crossref","first-page":"107872","DOI":"10.1016\/j.pharmthera.2021.107872","article-title":"Biased agonism in drug discovery: Is there a future for biased 5-HT1A receptor agonists in the treatment of neuropsychiatric diseases?","volume":"227","author":"Salaciak","year":"2021","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1285","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1016\/j.neuropharm.2017.07.022","article-title":"Antinociceptive, antiallodynic and antihyperalgesic effects of the 5-HT1A receptor selective agonist, NLX-112 in mouse models of pain","volume":"125","author":"Salat","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1290","doi-asserted-by":"crossref","first-page":"21966","DOI":"10.1073\/pnas.0912257106","article-title":"Loss of MeCP2 in aminergic neurons causes cell-autonomous defects in neurotransmitter synthesis and specific behavioral abnormalities","volume":"106","author":"Samaco","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1295","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1124\/mol.107.035337","article-title":"Ligand-directed signaling at the beta3-adrenoceptor produced by 3-(2-Ethylphenoxy)-1-[(1,S)-1,2,3,4-tetrahydronapth-1-ylamino]-2S-2-propanol oxalate (SR59230A) relative to receptor agonists","volume":"72","author":"Sato","year":"2007","journal-title":"Molecular Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1300","first-page":"21","article-title":"Antidepressants as analgesics: An overview of central and peripheral mechanisms of action","volume":"26","author":"Sawynok","year":"2001","journal-title":"Journal of Psychiatry & Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1305","doi-asserted-by":"crossref","first-page":"845","DOI":"10.1038\/nrd2087","article-title":"Novel pharmacological targets for the treatment of Parkinson\u2019s disease","volume":"5","author":"Schapira","year":"2006","journal-title":"Nature Reviews. Drug Discovery"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1310","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/0014-2999(80)90141-7","article-title":"Serotonin receptors in hippocampus and frontal cortex","volume":"66","author":"Seeman","year":"1980","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1315","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1186\/s40478-018-0653-7","article-title":"Regulation of dopamine neurotransmission from serotonergic neurons by ectopic expression of the dopamine D2 autoreceptor blocks levodopa-induced dyskinesia","volume":"7","author":"Sellnow","year":"2019","journal-title":"Acta Neuropathologica Communications"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1320","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.pharmthera.2019.05.006","article-title":"Biased signaling of G protein coupled receptors (GPCRs): Molecular determinants of GPCR\/transducer selectivity and therapeutic potential","volume":"200","author":"Seyedabadi","year":"2019","journal-title":"Pharmacology & Therapeutics"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1325","doi-asserted-by":"crossref","first-page":"108155","DOI":"10.1016\/j.neuropharm.2020.108155","article-title":"Central 5-HT receptors and their function; present and future","volume":"177","author":"Sharp","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1330","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1111\/j.1476-5381.1989.tb14630.x","article-title":"Pharmacological characterization of 8-OH-DPAT-induced inhibition of rat hippocampal 5-HT release in vivo as measured by microdialysis","volume":"98","author":"Sharp","year":"1989","journal-title":"British Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1335","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1002\/(SICI)1098-2396(199702)25:2<147::AID-SYN5>3.0.CO;2-C","article-title":"P-[18F]-MPPF: A potential radioligand for PET studies of 5-HT1A receptors in humans","volume":"25","author":"Shiue","year":"1997","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1340","doi-asserted-by":"crossref","first-page":"3243","DOI":"10.1016\/j.neuroimage.2011.11.029","article-title":"Serotonin-1A receptors in major depression quantified using PET: Controversies, confounds, and recommendations","volume":"59","author":"Shrestha","year":"2012","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1345","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.neuroimage.2010.01.055","article-title":"D2 dopamine receptor internalization prolongs the decrease of radioligand binding after amphetamine: A PET study in a receptor internalization-deficient mouse model","volume":"50","author":"Skinbjerg","year":"2010","journal-title":"Neuroimage"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1350","doi-asserted-by":"crossref","first-page":"10946","DOI":"10.1021\/acs.jmedchem.0c00814","article-title":"Discovery of novel pERK1\/2- or beta-Arrestin-preferring 5-HT1A receptor-biased agonists: Diversified therapeutic-like versus side effect profile","volume":"63","author":"Sniecikowska","year":"2020","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1355","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1021\/acs.jmedchem.9b00062","article-title":"Novel aryloxyethyl derivatives of 1-(1-benzoylpiperidin-4-yl)methanamine as the extracellular regulated kinases 1\/2 (ERK1\/2) phosphorylation-preferring serotonin 5 HT1A receptor biased agonists with robust antidepressant-like activity","volume":"62","author":"Sniecikowska","year":"2019","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1360","doi-asserted-by":"crossref","first-page":"2393","DOI":"10.2174\/1568026619666190911122040","article-title":"From receptor selectivity to functional selectivity: The rise of biased Agonism in 5-HT1A receptor drug discovery","volume":"19","author":"Sniecikowska","year":"2019","journal-title":"Current Topics in Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1365","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.neuropharm.2003.08.007","article-title":"8-OH-DPAT as a 5-HT7 agonist: Phase shifts of the circadian biological clock through increases in cAMP production","volume":"46","author":"Sprouse","year":"2004","journal-title":"Neuropharmacology"},{"issue":"1","key":"10.1016\/j.pharmthera.2021.107937_bb1370","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1111\/j.1743-6109.2010.02032.x","article-title":"Multifunctional pharmacology of Flibanserin: Possible mechanism of therapeutic action in hypoactive sexual desire disorder","volume":"8","author":"Stahl","year":"2011","journal-title":"The Journal of Sexual Medicine"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1375","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1007\/s00213-013-3164-z","article-title":"Aggression-reducing effects of F15599, a novel selective 5-HT1A receptor agonist, after microinjection into the ventral orbital prefrontal cortex, but not in infralimbic cortex in male mice","volume":"230","author":"Stein","year":"2013","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1380","doi-asserted-by":"crossref","first-page":"4824","DOI":"10.1016\/j.bmc.2015.05.042","article-title":"Arylpiperazine agonists of the serotonin 5-HT1A receptor preferentially activate cAMP signaling versus recruitment of beta-arrestin-2","volume":"23","author":"Stroth","year":"2015","journal-title":"Bioorganic & Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1385","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1002\/wmts.39","article-title":"Ligand-specific differential regulation of 5-hydroxytryptamine receptors: Functional selectivity in serotonergic signaling","volume":"1","author":"Stroth","year":"2012","journal-title":"WIREs Membrane Transport and Signaling"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107937_bb1390","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1093\/brain\/awu409","article-title":"Eltoprazine counteracts l-DOPA-induced dyskinesias in Parkinson\u2019s disease: A dose-finding study","volume":"138","author":"Svenningsson","year":"2015","journal-title":"Brain"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1395","doi-asserted-by":"crossref","first-page":"1713","DOI":"10.1152\/jn.00868.2015","article-title":"Systems-level neurophysiological state characteristics for drug evaluation in an animal model of levodopa-induced dyskinesia","volume":"115","author":"Tamte","year":"2016","journal-title":"Journal of Neurophysiology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1400","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1007\/s00259-006-0228-x","article-title":"Distribution of the 5-HT(1A) receptor antagonist [ (18)F]FPWAY in blood and brain of the rat with and without isoflurane anesthesia","volume":"34","author":"Tokugawa","year":"2007","journal-title":"European Journal of Nuclear Medicine and Molecular Imaging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1405","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/0014-2999(84)90714-3","article-title":"The involvement of subtypes of the 5-HT1 receptor and of catecholaminergic systems in the behavioural response to 8-hydroxy-2-(di-n-propylamino)tetralin in the rat","volume":"106","author":"Tricklebank","year":"1984","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1410","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1002\/syn.21835","article-title":"Optimising PET approaches to measuring 5-HT release in human brain","volume":"69","author":"Tyacke","year":"2015","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1415","doi-asserted-by":"crossref","first-page":"5070","DOI":"10.1021\/jm9804329","article-title":"Design and synthesis of a series of 6-substituted-2-pyridinylmethylamine derivatives as novel, high-affinity, selective agonists at 5-HT1A receptors","volume":"41","author":"Vacher","year":"1998","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1420","doi-asserted-by":"crossref","first-page":"1648","DOI":"10.1021\/jm9806906","article-title":"Novel derivatives of 2-pyridinemethylamine as selective, potent, and orally active agonists at 5-HT1A receptors","volume":"42","author":"Vacher","year":"1999","journal-title":"Journal of Medicinal Chemistry"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1425","series-title":"ANS\/AuPS joint meeting","article-title":"Can rats be trained to discriminate between pre- and post-synaptic serotonin1A receptors? Investigating the effects of novel anxiolytic and antidepressant compounds using drug discrimination","author":"Vacy","year":"2010"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1430","doi-asserted-by":"crossref","first-page":"404","DOI":"10.3389\/fnins.2019.00404","article-title":"Overcoming resistance to selective serotonin reuptake inhibitors: Targeting serotonin, serotonin-1A receptors and adult neuroplasticity","volume":"13","author":"Vahid-Ansari","year":"2019","journal-title":"Frontiers in Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1435","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1016\/j.coph.2010.09.004","article-title":"The role of conformational ensembles of seven transmembrane receptors in functional selectivity","volume":"10","author":"Vaidehi","year":"2010","journal-title":"Current Opinion in Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1440","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1017\/S1461145709990940","article-title":"Agonist-dependent modulation of G-protein coupling and transduction of 5-HT1A receptors in rat dorsal raphe nucleus","volume":"13","author":"Valdizan","year":"2010","journal-title":"The International Journal of Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1445","doi-asserted-by":"crossref","first-page":"S36","DOI":"10.1016\/S0924-977X(16)70041-1","article-title":"Chronic effects of \u201cbiased\u201d 5-HT1A receptor agonists on object pattern separation performance and hippocampal plasticity","volume":"26","author":"Van Hagen","year":"2016","journal-title":"European Neuropsychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1450","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.neurobiolaging.2009.01.008","article-title":"Effects of amyloid-beta peptides on the serotoninergic 5-HT1A receptors in the rat hippocampus","volume":"32","author":"Verdurand","year":"2011","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1455","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.neurobiolaging.2015.12.008","article-title":"Differential effects of amyloid-beta 1-40 and 1-42 fibrils on 5-HT1A serotonin receptors in rat brain","volume":"40","author":"Verdurand","year":"2016","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1460","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neuropharm.2017.06.021","article-title":"Hippocampal 5-HT1A receptor expression changes in prodromal stages of Alzheimer's disease: Beneficial or deleterious?","volume":"123","author":"Verdurand","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1465","doi-asserted-by":"crossref","first-page":"107867","DOI":"10.1016\/j.neuropharm.2019.107867","article-title":"Pharmacological MRI to investigate the functional selectivity of 5-HT1A receptor biased agonists","volume":"172","author":"Vidal","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1470","doi-asserted-by":"crossref","first-page":"2973","DOI":"10.1007\/s00429-018-1672-7","article-title":"(18)F-F13640 preclinical evaluation in rodent, cat and primate as a 5-HT1A receptor agonist for PET neuroimaging","volume":"223","author":"Vidal","year":"2018","journal-title":"Brain Structure & Function"},{"issue":"11","key":"10.1016\/j.pharmthera.2021.107937_bb1475","doi-asserted-by":"crossref","first-page":"2310","DOI":"10.1038\/s41386-018-0145-2","article-title":"In vivo biased agonism at 5-HT1A receptors: Characterisation by simultaneous PET\/MR imaging","volume":"43","author":"Vidal","year":"2018","journal-title":"Neuropsychopharmacology."},{"key":"10.1016\/j.pharmthera.2021.107937_bb1480","doi-asserted-by":"crossref","DOI":"10.3233\/JPD-212580","article-title":"Different alterations of agonist and antagonist binding to 5-HT1A receptor in a rat model of Parkinson\u2019s disease and levodopa-induced dyskinesia: A microPET study","author":"Vidal","year":"2021","journal-title":"Journal of Parkinson Disease"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1485","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.neuropharm.2016.05.009","article-title":"Agonist and antagonist bind differently to 5-HT1A receptors during Alzheimer's disease: A post-mortem study with PET radiopharmaceuticals","volume":"109","author":"Vidal","year":"2016","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1490","doi-asserted-by":"crossref","first-page":"11521","DOI":"10.1523\/JNEUROSCI.4373-05.2005","article-title":"Mecp2 deficiency disrupts norepinephrine and respiratory systems in mice","volume":"25","author":"Viemari","year":"2005","journal-title":"The Journal of Neuroscience"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1495","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1016\/0028-3908(95)00013-V","article-title":"Stimulation of median, but not dorsal, raphe 5-HT1A autoreceptors by the local application of 8-OH-DPAT reverses raclopride-induced catalepsy in the rat","volume":"34","author":"Wadenberg","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1500","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/S0028-3908(98)00162-2","article-title":"Effects of local application of 5-hydroxytryptamine into the dorsal or median raphe nuclei on haloperidol-induced catalepsy in the rat","volume":"38","author":"Wadenberg","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1505","series-title":"xPharm: The comprehensive pharmacology reference","article-title":"8-OH-DPAT","author":"Wallace","year":"2007"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1510","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1016\/0361-9230(94)90143-0","article-title":"The dorsal raphe: An important nucleus in pain modulation","volume":"34","author":"Wang","year":"1994","journal-title":"Brain Research Bulletin"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1515","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.890210211","article-title":"Spare receptors and intrinsic activity: Studies with D1 dopamine receptor agonists","volume":"21","author":"Watts","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1520","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1016\/0014-2999(96)00150-1","article-title":"Ipsapirone enhances the dopamine outflow via 5-HT1A receptors in the rat prefrontal cortex","volume":"305","author":"Wedzony","year":"1996","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1525","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1203\/01.pdr.0000238302.84552.d0","article-title":"Autonomic nervous system dysregulation: Breathing and heart rate perturbation during wakefulness in young girls with Rett syndrome","volume":"60","author":"Weese-Mayer","year":"2006","journal-title":"Pediatric Research"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1530","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1016\/j.ynstr.2016.08.002","article-title":"The chronic mild stress (CMS) model of depression: History, evaluation and usage","volume":"6","author":"Willner","year":"2017","journal-title":"Neurobiol Stress"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1535","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1016\/S0149-7634(05)80194-0","article-title":"Chronic mild stress-induced anhedonia: A realistic animal model of depression","volume":"16","author":"Willner","year":"1992","journal-title":"Neuroscience and Biobehavioral Reviews"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1540","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/BF00165727","article-title":"Evidence for various tryptamines and related compounds acting as substrates of the platelet 5-hydroxytryptamine transporter","volume":"345","author":"Wolfel","year":"1992","journal-title":"Naunyn-Schmiedeberg\u2019s Archives of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1545","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/0014-2999(88)90651-6","article-title":"Flesinoxan lowers blood pressure and heart rate in cats via 5-HT1A receptors","volume":"149","author":"Wouters","year":"1988","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1550","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ejphar.2003.08.047","article-title":"The very-high-efficacy 5-HT1A receptor agonist, F 13640, preempts the development of allodynia-like behaviors in rats with spinal cord injury","volume":"478","author":"Wu","year":"2003","journal-title":"European Journal of Pharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1555","doi-asserted-by":"crossref","first-page":"1066","DOI":"10.1016\/S0026-895X(25)09248-X","article-title":"Lack of apparent receptor reserve at postsynaptic 5-hydroxytryptamine1A receptors negatively coupled to adenylyl cyclase activity in rat hippocampal membranes","volume":"41","author":"Yocca","year":"1992","journal-title":"Molecular Pharmacology"},{"issue":"12","key":"10.1016\/j.pharmthera.2021.107937_bb1560","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/ijnp\/pyw079","article-title":"Marmoset serotonin 5-HT1A receptor mapping with a biased agonist PET probe 18F-F13714: Comparison with an antagonist tracer 18F-MPPF in awake and anesthetized states","volume":"19","author":"Yokoyama","year":"2016","journal-title":"The International Journal of Neuropsychopharmacology"},{"issue":"4","key":"10.1016\/j.pharmthera.2021.107937_bb1565","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00213-018-5124-0","article-title":"Activation of somatodendritic 5-HT1A autoreceptors reduces the acquisition and expression of cued fear in the rat fear-potentiated startle test","volume":"236","author":"Zhao","year":"2019","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1570","doi-asserted-by":"crossref","first-page":"80111","DOI":"10.18632\/oncotarget.13418","article-title":"Pharmacological agonists for more-targeted CNS radio-pharmaceuticals","volume":"7","author":"Zimmer","year":"2016","journal-title":"Oncotarget"},{"key":"10.1016\/j.pharmthera.2021.107937_bb1575","doi-asserted-by":"crossref","first-page":"608","DOI":"10.1016\/j.tips.2017.04.001","article-title":"Contribution of clinical neuroimaging to the understanding of the pharmacology of methylphenidate","volume":"38","author":"Zimmer","year":"2017","journal-title":"Trends in Pharmacological Sciences"}],"container-title":["Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582100139X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016372582100139X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,27]],"date-time":"2025-09-27T22:16:27Z","timestamp":1759011387000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016372582100139X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":315,"alternative-id":["S016372582100139X"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107937","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Translating biased agonists from molecules to medications: Serotonin 5-HT1A receptor functional selectivity for CNS disorders","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2021.107937","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"107937"}}